Safety and Observations in a Pilot Study of Lenalidomide for Treatment in Autism

Table 2

Parameter estimates for each subject who underwent pharmacokinetic testing at 1, 2, 4, and 8 hours.

ID	𝐶max (ng/mL)	𝑡max (h)	AUCT (ng/mL)
1	23.35	1	112.35
2	52.06	2	167.36
3	54.41	1	179.19
4	57.74	1	219.72
5	153.57	1	327.54
6	60.64	2	281.29
7	19.46	1	59.39
Mean	60.18	1.29	192.41
SD	44.43	0.49	92.93